ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission

Key Takeaways IBRX surged 17.4% after FDA talks aligned on the regulatory path for Anktiva in papillary NMIBC.ImmunityBio finished the requested analyses and plans an sBLA resubmission within a month, with no new study.IBRX's QUILT-3.032 study (Cohort B) met its endpoint, showing durable clinical efficacy with Anktiva.Shares of ImmunityBio (IBRX) surged 17.4% after it announced a recent face-to-face meeting with senior FDA officials to align on the regulatory path forward for Anktiva in an additional indica ...